BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 3329524)

  • 1. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
    Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
    Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
    Owellen RJ; Hartke CA; Dickerson RM; Hains FO
    Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of guanine nucleotides on vincristine binding in tumor cytosols and purified tubulin: evidence for an inhibitor of vincristine binding.
    Bowman LC; Houghton JA; Houghton PJ
    J Cell Physiol; 1990 Sep; 144(3):376-82. PubMed ID: 2391373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calmodulin, activated cyclic nucleotide phosphodiesterase, microtubules, and vinca alkaloids.
    Watanabe K; West WL
    Fed Proc; 1982 May; 41(7):2292-9. PubMed ID: 6122611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivatives of 5,6-diphenylpyridazin-3-one: synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site.
    Batra JK; Powers LJ; Hess FD; Hamel E
    Cancer Res; 1986 Apr; 46(4 Pt 2):1889-93. PubMed ID: 3948171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma and normal tissues of the mouse.
    Houghton JA; Williams LG; Houghton PJ
    Cancer Res; 1985 Aug; 45(8):3761-7. PubMed ID: 2990677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
    Houghton JA; Williams LG; Torrance PM; Houghton PJ
    Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The binding of vinca domain agents to tubulin: structural and biochemical studies.
    Cormier A; Knossow M; Wang C; Gigant B
    Methods Cell Biol; 2010; 95():373-90. PubMed ID: 20466145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Block of axoplasmic transport in vitro by vinca alkaloids.
    Chan SY; Worth R; Ochs S
    J Neurobiol; 1980 May; 11(3):251-64. PubMed ID: 6156229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP; Kavallaris M
    Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro.
    Himes RH; Kersey RN; Heller-Bettinger I; Samson FE
    Cancer Res; 1976 Oct; 36(10):3798-802. PubMed ID: 954003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms.
    Sirotnak FM; Danenberg KD; Chen J; Fritz F; Danenberg PV
    Biochem Biophys Res Commun; 2000 Mar; 269(1):21-4. PubMed ID: 10694470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of estramustine with tubulin isotypes.
    Laing N; Dahllöf B; Hartley-Asp B; Ranganathan S; Tew KD
    Biochemistry; 1997 Jan; 36(4):871-8. PubMed ID: 9020786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL
    Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.